US20200015775A1 - Method of characterizing the pathological response of tissue to a treatment plan - Google Patents

Method of characterizing the pathological response of tissue to a treatment plan Download PDF

Info

Publication number
US20200015775A1
US20200015775A1 US16/367,362 US201916367362A US2020015775A1 US 20200015775 A1 US20200015775 A1 US 20200015775A1 US 201916367362 A US201916367362 A US 201916367362A US 2020015775 A1 US2020015775 A1 US 2020015775A1
Authority
US
United States
Prior art keywords
tissue
generating
treatment plan
tumor
acoustic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/367,362
Inventor
Peter John Littrup
Nebojsa Duric
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delphinus Medical Technologies Inc
Original Assignee
Delphinus Medical Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delphinus Medical Technologies Inc filed Critical Delphinus Medical Technologies Inc
Priority to US16/367,362 priority Critical patent/US20200015775A1/en
Assigned to DELPHINUS MEDICAL TECHNOLOGIES, INC. reassignment DELPHINUS MEDICAL TECHNOLOGIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DURIC, NEBOJSA, LITTRUP, PETER JOHN
Publication of US20200015775A1 publication Critical patent/US20200015775A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/08Detecting organic movements or changes, e.g. tumours, cysts, swellings
    • A61B8/0833Detecting organic movements or changes, e.g. tumours, cysts, swellings involving detecting or locating foreign bodies or organic structures
    • A61B8/085Detecting organic movements or changes, e.g. tumours, cysts, swellings involving detecting or locating foreign bodies or organic structures for locating body or organic structures, e.g. tumours, calculi, blood vessels, nodules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4848Monitoring or testing the effects of treatment, e.g. of medication
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/08Detecting organic movements or changes, e.g. tumours, cysts, swellings
    • A61B8/0825Detecting organic movements or changes, e.g. tumours, cysts, swellings for diagnosis of the breast, e.g. mammography
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/08Detecting organic movements or changes, e.g. tumours, cysts, swellings
    • A61B8/0833Detecting organic movements or changes, e.g. tumours, cysts, swellings involving detecting or locating foreign bodies or organic structures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/40Positioning of patients, e.g. means for holding or immobilising parts of the patient's body
    • A61B8/406Positioning of patients, e.g. means for holding or immobilising parts of the patient's body using means for diagnosing suspended breasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/46Ultrasonic, sonic or infrasonic diagnostic devices with special arrangements for interfacing with the operator or the patient
    • A61B8/461Displaying means of special interest
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/46Ultrasonic, sonic or infrasonic diagnostic devices with special arrangements for interfacing with the operator or the patient
    • A61B8/461Displaying means of special interest
    • A61B8/466Displaying means of special interest adapted to display 3D data
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/46Ultrasonic, sonic or infrasonic diagnostic devices with special arrangements for interfacing with the operator or the patient
    • A61B8/467Ultrasonic, sonic or infrasonic diagnostic devices with special arrangements for interfacing with the operator or the patient characterised by special input means
    • A61B8/469Ultrasonic, sonic or infrasonic diagnostic devices with special arrangements for interfacing with the operator or the patient characterised by special input means for selection of a region of interest
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/48Diagnostic techniques
    • A61B8/483Diagnostic techniques involving the acquisition of a 3D volume of data
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/52Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/5207Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves involving processing of raw data to produce diagnostic data, e.g. for generating an image
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/52Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/5215Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves involving processing of medical diagnostic data
    • A61B8/5223Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves involving processing of medical diagnostic data for extracting a diagnostic or physiological parameter from medical diagnostic data
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/52Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/5215Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves involving processing of medical diagnostic data
    • A61B8/5238Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves involving processing of medical diagnostic data for combining image data of patient, e.g. merging several images from different acquisition modes into one image
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00Image analysis
    • G06T7/0002Inspection of images, e.g. flaw detection
    • G06T7/0012Biomedical image inspection
    • G06T7/0014Biomedical image inspection using an image reference approach
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/43Detecting, measuring or recording for evaluating the reproductive systems
    • A61B5/4306Detecting, measuring or recording for evaluating the reproductive systems for evaluating the female reproductive systems, e.g. gynaecological evaluations
    • A61B5/4312Breast evaluation or disorder diagnosis
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00Indexing scheme for image analysis or image enhancement
    • G06T2207/10Image acquisition modality
    • G06T2207/10132Ultrasound image
    • G06T2207/101363D ultrasound image
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00Indexing scheme for image analysis or image enhancement
    • G06T2207/30Subject of image; Context of image processing
    • G06T2207/30004Biomedical image processing
    • G06T2207/30068Mammography; Breast

Definitions

  • This invention relates generally to the medical field, and more specifically to an improved method of characterizing the pathological response of tissue to a treatment plan in the cancer treatment field.
  • Common treatments for cancer include removal of cancerous tumor tissue from the patient, radiation treatment, chemotherapy, or ablation interventions, but the most effective treatment or combinations of treatments typically varies from patient to patient. For example, not all cancer patients respond to certain treatments like chemotherapy and radiation treatment, and furthermore not all responsive cancer patients have equal success with these treatments.
  • the success of a treatment for a patient is often not known until the end of the treatment or after a follow-up period after the treatment. However, it is advantageous to be able to accurately predict whether a patient will respond well to a treatment, particularly earlier in the treatment plan, to guide implementation of alternative regimens and/or to abort an unsuccessful treatment plan.
  • FIG. 1 is a schematic of the method of a preferred embodiment
  • FIG. 2 is a schematic of a scanner that may be used during the step of obtaining a set of sequential morphological renderings of tissue in the method of a preferred embodiment
  • FIG. 3A , FIG. 3B , FIG. 3C , and FIG. 3D are schematics of steps of obtaining a set of sequential morphological renderings of tissue in the method of a preferred embodiment
  • FIG. 4 is a schematic of the step of generating a set of representative values in the method of a preferred embodiment
  • FIG. 5 and FIG. 6 are schematics of variations of determining a trend of the biomechanical property based on a set of representative values of a biomechanical property in the method of a preferred embodiment.
  • FIG. 7 is a schematic of one variation of predicting response of tissue to a treatment plan based on the trend of a biomechanical property in the method of a preferred embodiment.
  • the method 100 of characterizing the pathological response of tissue to a treatment plan of a preferred embodiment includes the steps of: obtaining a set of sequential morphology renderings of the tissue S 110 , wherein each rendering corresponds to a particular point in time during the treatment plan; generating a set of representative values of a biomechanical property of the tissue for the set of renderings S 120 , wherein each representative value is based on a corresponding rendering; determining a trend of the biomechanical property S 130 based on the set of representative values; and predicting response of the tissue to the treatment plan S 140 based on the trend of the biomechanical property.
  • the method 100 is preferably used to predict and/or monitor the pathological response of cancer, such as breast cancer, to chemotherapy or radiation therapy (or side effects of the therapy), but may additionally and/or alternatively be used to predict or monitor the response of any cancer or benign tumors to any suitable treatment.
  • the method 100 may additionally and/or alternatively be used to predict success of chemoprevention (a pharmacological approach to reducing cancer risk). Predicting and characterizing how a cancer patient will respond to a particular cancer treatment allows a physician to distinguish patients who are likely to have success with the treatment from those patients who are less likely to have success with the treatment, thereby allowing the physician to guide implementation of alternative regimens and/or to abort the particular treatment.
  • Such knowledge about patient response to the treatment enables the physician to, for example, spare an unresponsive patient from suffering side effects of chemotherapy or radiation therapy and from applying potentially limited financial means towards an ineffective treatment, and move towards optimizing the efficacy of a treatment plan.
  • the trend, such as rate of change, of the biomechanical property of the tumor early in the treatment plan is preferably used to predict the full treatment response, but the trend of the biomechanical property at any stage in the treatment plan may additionally and/or alternatively be used.
  • the method 100 may facilitate an accurate and frequent evaluation of the tumor response to other therapies, such as to evaluate the clinical efficacy of a new therapeutic agent or regimen.
  • the step of obtaining a set of sequential morphology renderings S 110 functions to obtain data from the patient. This data forms the basis of analysis in characterizing the response of the tissue to a cancer treatment.
  • the morphology renderings preferably include renderings of tumor tissue, and may additionally and/or alternatively include renderings of healthy tissue such as that surrounding the tumor tissue.
  • the morphology renderings may additionally and/or alternatively broken bones or any suitable tissue.
  • Each rendering preferably corresponds to a particular point in time during the treatment plan, such that the set of renderings represent sequential, chronological snapshots of the tissue at various points in time during the treatment plan.
  • obtaining a rendering may be performed hourly, daily, every few days, every 1-3 weeks, or any suitable frequency, or performed in correspondence (e.g., immediately before and/or immediately after) a treatment phase such as a chemotherapy treatment.
  • Obtaining a set of renderings S 110 is preferably performed in early stages of a treatment plan (e.g., within the first several months), but may alternatively be performed during any suitable portion of the treatment plan.
  • the set of renderings may be taken at approximately regular time intervals during the treatment plan, or at irregular time intervals (for example, the timing of the renderings may depend on particular scheduling of chemotherapy treatments).
  • obtaining a set of renderings S 110 preferably includes scanning the tissue with an ultrasound scanner to obtain acoustic data S 112 and creating images representing acoustic parameters of the tissue with the acoustic data S 114 .
  • the steps of scanning the tissue and creating images are each preferably performed at least once each time a single rendering is obtained, such that the steps of scanning the tissue and creating images are repeated multiple times.
  • Obtaining a set of renderings S 110 may additionally and/or alternatively include retrieving a set of images or renderings from a storage device such as a hard drive or an online server, or any suitable storage such as hard copy patient records.
  • the step of scanning the tissue S 112 preferably includes surrounding the tissue with a transducer that transmits and receives acoustic waves through the tissue.
  • a transducer that transmits and receives acoustic waves through the tissue.
  • FIG. 2 and FIG. 3A to scan breast tissue of a breast cancer patient with an ultrasound tomography scanner having a ring-shaped transducer, the patient positions themselves face down on a flexible bed having a hole in the chest region of the bed. The breast of the patient passes through the hole in the bed and is positioned within the transducer immersed in a water bath.
  • the ring transducer is preferably fixed to a gantry, and, during the scanning step S 112 , moves in a vertical path to pass between the chest wall and the nipple region in an anterior-posterior direction, thereby preferably imaging the entire breast (alternatively a selected portion of the breast).
  • the scanner is preferably similar to that described in U.S. Patent Publication No. 2008/0275344 entitled “Method and apparatus for categorizing breast density and assessing cancer risk utilizing acoustic parameters”, which is incorporated in its entirety by this reference.
  • the ring transducer may be used to scan any suitable tissue, such as an arm, hand, leg, or foot.
  • the scanner is preferably relatively inexpensive, quick, and more comfortable for the patient and easy to install and operate.
  • the scanning step preferably gathers acoustic data including acoustic reflection from tissue, acoustic attenuation within tissue, and/or acoustic speed within tissue.
  • the scanning step may additionally and/or alternatively gather any other acoustic data or suitable biomechanical property of the tissue.
  • the method may alternatively include obtaining a set of morphology renderings using magnetic resonance imaging (MRI), positron emission tomography (PET), or any suitable device to generate renderings of tissue.
  • MRI magnetic resonance imaging
  • PET positron emission tomography
  • PET may be used to assess metabolic changes in tissue to generate tissue images.
  • the step of creating images representing acoustic parameters of the tissue S 114 preferably includes generating one or more two-dimensional (2D) images from the acoustic data obtained during the scanning step, and may include generating one or more three-dimensional (3D) images of the tissue.
  • generating one or more 2D images includes generating a plurality of 2D cross-sectional images (e.g., “slices” in the coronal plane, or any suitable plane) of the tissue S 116 and combining the 2D cross-sectional images of the tissue into a 3D image of the tissue S 118 .
  • the images are preferably tomography images, and more preferably ultrasound tomography images, although they may alternatively be any suitable tomography images.
  • a general process for combining stacks of 2D images into a 3D image is known by one skilled in the art, but one possible process is described in U.S. Patent Publication No. 2008/0275344.
  • the 2D and/or 3D images may be generated in any suitable manner.
  • the steps of scanning and creating images are preferably repeated until a chronological set of renderings of the tissue (preferably 3D) are obtained, such that the set includes a morphological rendering at times t 1 , t 2 , t 3 . .
  • the images preferably represent at least one of acoustic reflection from the tissue, acoustic attenuation within the tissue, and acoustic speed within the tissue.
  • the images may additionally and/or alternatively represent any suitable biomechanical property of the tissue.
  • the images may represent the tissue under Doppler radar or the interaction of the tissue with a contrast agent (e.g., uptake or kinetics of flow). As shown in FIG.
  • each acoustic parameter is preferably imaged in a separate stack of 2D images, such that at each cross-sectional level in the stack, the images for acoustic reflection (Ir), attenuation (Ia), and/or acoustic speed (Is) can be overlaid or combined into a merged 2D image.
  • Ir acoustic reflection
  • Ia attenuation
  • Is acoustic speed
  • the step of generating a set of representative values of a biomechanical property S 120 functions to quantify or otherwise characterize the biomechanical property in the set of renderings.
  • the step of generating a set of representative values S 120 preferably includes calculating an average value of the biomechanical property for each rendering S 122 , thereby generating a set of sequential or chronological volume average values of the biomechanical property of the tissue.
  • Generating a set of representative values S 120 may further include normalizing the set of representative values, such as to remove statistical error from the measured data.
  • the generated representative values of the set of renderings are preferably of acoustic speed, but may additionally and/or include acoustic attenuation, acoustic speed, tissue density, and/or any suitable biomechanical property.
  • the average value is a volume average of the biomechanical property in a primary tumor in the patient.
  • the primary tumor is preferably defined by locating an outline of the tumor mass as it appears on the morphology renderings of the acoustic reflection image, and the tumor outline may be replicated on the acoustic attenuation and/or acoustic speed morphology renderings to show the boundary of the primary tumor.
  • the volume average preferably incorporates the mean value of the biomechanical property within the volume of the primary tumor as characterized by the renderings. For example, an average volumetric acoustic speed may be calculated as described in U.S. Patent Publication No. 2008/0275344.
  • the volume average may be a representative value of the biomechanical property in the primary tumor calculated in any suitable manner.
  • the volume average may additionally and/or alternatively include other aspects, such as being weighted by a spatial distribution of the values of the biomechanical property throughout the primary tumor.
  • the volume average may take into account a combination of multiple different kinds of biomechanical properties throughout the primary tumor.
  • the average value may be the mean or other statistical average of multiple volume averages of the multiple tumors, or the maximum volume average value of the multiple volume averages of multiple tumors. In another variation, the average value is the mean or other statistical average of any suitable healthy or unhealthy portion of the rendered tissue. However, the average value may alternatively be any suitable average value.
  • Calculating an average value of the biomechanical property for each rendering S 122 preferably includes accounting for the difference between the value of the biomechanical property within the tumor tissue and the value of the biomechanical property in background tissue surrounding the tumor tissue S 124 . Accounting for the difference functions to disregard the value of the biomechanical property in the background tissue. Preferably, accounting for the difference S 124 includes subtracting an average value of the biomechanical property in background tissue from the volume average value of the biomechanical property of the tumor tissue S 126 , but the difference may be accounted for in any suitable manner.
  • the boundary of background tissue relative to tumor tissue in each rendering may be defined in one or more of several manners.
  • the background tissue may be defined as a region beyond a distance threshold (e.g., 2 centimeters) beyond the boundary of the outlined tumor tissue.
  • the background tissue may be defined as a region beyond a boundary where the gradient in the biomechanical property satisfies a difference threshold.
  • the boundary of background tissue relative to tumor tissue may be defined in any suitable manner.
  • generating a set of representative values S 120 includes determining an initial or baseline value of the biomechanical property, or any suitable singular value of the biomechanical property.
  • the initial value may be taken from the first rendering obtained in step S 110 .
  • determining a trend of the biomechanical property S 130 may include characterizing initial values of multiple biomechanical properties, or any suitable singular values of multiple biomechanical properties.
  • generating a set of representative values S 120 may include characterizing the spatial distribution of the biomechanical property in each of the set of renderings.
  • the characterization may be qualitative, or may be quantitative such as by generating a parameter descriptive of the spatial distribution of the biomechanical property.
  • Generating a set of representative values S 120 may include characterizing the spatial distribution of acoustic speed in an acoustic rendering, but may additionally and/or alternatively include characterizing the spatial distribution of acoustic attenuation or any suitable biomechanical property.
  • the step of determining a trend of the biomechanical property S 130 functions to generate metrics, based on the acoustic data, that may be analyzed for predicting or otherwise characterizing patient response to a treatment plan. Determining a trend S 130 preferably includes calculating a rate of change in the set of average values S 132 , which may be one or more of several variations. In a first variation, as shown in FIG. 6 , determining a trend of the biomechanical property S 130 includes graphing the set of average values of the biomechanical property on a plot against a temporal variable (e.g., number of days of treatment or number of treatments) S 134 .
  • a temporal variable e.g., number of days of treatment or number of treatments
  • Each value of the set of average values may be expressed as an absolute value, expressed as a percentage of the first average value of the set, or in any suitable manner.
  • calculating a rate of change S 132 preferably includes calculating a slope of a best-fit curve fitted to at least a portion of the plot.
  • the calculated rate of change in the biomechanical property may be the slope of a best-fit curve fitted to two or more values in the set of volume average values.
  • the calculated rate of change may be the slope between the first and last average values, the mean or median of slopes between subsets of adjacent pairs of average values, percentage difference between two or more points on the plots, or any suitable statistical measure of rate of change in the plot.
  • the calculated rate of change may or may not be displayed on the plot.
  • determining a trend of the biomechanical property S 130 includes mathematically calculating the rate of change.
  • the calculation may be similar to the first variation except the computation is performed without graphing the set of average values on a plot.
  • determining a trend of the biomechanical property S 130 includes determining a trend of multiple biomechanical properties.
  • initial values of multiple biomechanical properties may be characterized relative to each other, such as by plotting (or comparing in any suitable manner, such as by calculating a ratio) the initial value of one biomechanical property against another biomechanical property.
  • the initial value of acoustic speed of the tissue may be compared to the initial value of acoustic attenuation of the tissue.
  • multiple time-dependent representative values (e.g., chronological average values) of one biomechanical property may be compared to those of another biomechanical property, such as on a multi-dimensional plot having time-dependent values of acoustic speed on one axis, time-dependent values of acoustic attenuation on another axis, and potentially a temporal variable on a third axis, or on a plot having a ratio of two biomechanical properties on one axis and a temporal variable on another axis.
  • determining a trend of the biomechanical property S 132 may include graphing the set of average values of the biomechanical property on a plot against a temporal variable, similar to the plot of the first variation, and characterizing the general shape of the curve formed by the plot.
  • the general shape (e.g., a plateau) of the curve may be characterized quantitatively and/or qualitatively.
  • the trend of the biomechanical property shown on the plot may be described as having a certain type of slope or plateau indicating an approximately degree of gradient or flatness, respectively.
  • the step of predicting response of the tissue S 140 based on the trend of the biomechanical property functions to characterize the tissue response to the treatment plan.
  • the trend of the biomechanical property may be assessed for change in tissue properties, such as for long-term multiple stage intervention like chemotherapy and radiation therapy, or for cell death as a result of ablation interventions like cryotherapy, radiofrequency (RF) ablation, or electroporation.
  • predicting response of the tissue S 140 preferably includes comparing the rate of change to a threshold S 142 .
  • the threshold may be quantitative, or qualitative.
  • the threshold is preferably based on data characterizing the response of prior patients to the treatment plan, such that prior patients undergoing the treatment plan form a baseline to which current patients may be compared.
  • thresholds may be determined with prior experimental data of patients who were scanned and analyzed according to the preferred method. Some or all of these prior patients may have completed the treatment plan, and additional means such as MRI or PET scans may have been used to determine whether these patients responded or did not respond to the treatment plan, and to what degree of success the responsive patients had with the treatment plan. Analysis of prior patients' experimental data may yield multiple thresholds that indicate varying thresholds of predicted responsiveness (e.g., “complete”, “partial”, or “nonresponsive”) to the treatment plan.
  • the threshold may be a “success” threshold, such that if the rate of change (or any singular value, such as an initial baseline value) of the biomechanical property is at and/or above the success threshold, the patient is predicted to respond positively to the continued treatment plan. Furthermore, in this variation, if the rate of change does not meet the success threshold, then the patient is predicted to not respond favorably to the treatment. The exact comparison of the rate of change or other trend relative to the threshold depends on the specific biomechanical property. For example, if the rate of change in acoustic speed in a primary tumor in a particular patient is a declining slope that is steeper than the slope of the success threshold, then the particular patient is predicted to respond positively to the continued treatment plan. However, for other biomechanical properties, the patient may be predicted to respond positively if the rate of change is an inclining slope that is steeper than the slope of the success threshold. Alternatively, the threshold may be considered a “fail” threshold.
  • Predicting response of the tissue S 140 may be additionally and/or alternatively include any suitable characteristic of the set of average values of the biomechanical property.
  • predicting response of the tissue S 140 includes analyzing the general shape of the curve formed by a plot of the set of average values against a temporal variable.
  • predicting response of the tissue S 140 includes analyzing the initial starting value of biomechanical property in the set of average values.
  • predicting response of the tissue S 140 includes analyzing the trend of one or more biomechanical property and/or morphological characteristic relative to another biomechanical property and/or morphological characteristic.
  • analyzing the trend may include analyzing the spread or distribution of values on a multi-dimensional plot that has values of one biomechanical property (e.g., acoustic speed) on one axis, values of another biomechanical property (e.g., acoustic attenuation), and potentially a temporal variable on a third axis.
  • analyzing the trend may include analyzing the trend of the ratio between two biomechanical properties (or general shape of the curve formed by a plot of the ratios against a temporal variable).
  • the method may further include modifying the treatment plan based on the predicted response S 150 , which functions to utilize the predicted response of the tissue to most benefit the patient. For example, if the prediction is that the patient will respond favorably to the treatment plan, then the step of modifying the treatment plan based on the predicted response S 150 may include maintaining the current treatment plan and/or continuing to monitor the physiological response of the patient. As another example, if the prediction is that the patient will not respond favorably to the treatment, then the step of modifying the treatment plan may include: altering characteristics of the treatment plan (such as type of dose, dosage amount, dosage frequency, or distribution pattern of radiation or ablation), administering a different kind of treatment, or aborting the treatment plan. Other suitable modifications, dependent on the specific nature and status of the patient as known by one skilled in the art, may be at the physician's discretion.
  • altering characteristics of the treatment plan such as type of dose, dosage amount, dosage frequency, or distribution pattern of radiation or ablation

Abstract

A method of characterizing the pathological response of tissue to a treatment plan, including: obtaining a set of sequential morphology renderings of the tissue, wherein each rendering corresponds to a particular point in time during the treatment plan; generating a set of representative values of a biomechanical property of the tissue for the set of renderings, wherein each representative value is based on a corresponding rendering; determining a trend of the biomechanical property based on the set of representative values; and predicting response of the tissue to the treatment plan based on the trend of the biomechanical property.

Description

    CROSS-REFERENCE
  • This application is a continuation of U.S. patent application Ser. No. 14/835,349, filed 25 Aug. 2015, which is a continuation of U.S. patent application Ser. No. 13/027,036, filed 14 Feb. 2011, now U.S. Pat. No. 9,144,403, which claims the benefit of U.S. Provisional Application No. 61/304,256 filed 12 Feb. 2010, each of which are incorporated in their entirety by this reference.
  • TECHNICAL FIELD
  • This invention relates generally to the medical field, and more specifically to an improved method of characterizing the pathological response of tissue to a treatment plan in the cancer treatment field.
  • BACKGROUND
  • Common treatments for cancer include removal of cancerous tumor tissue from the patient, radiation treatment, chemotherapy, or ablation interventions, but the most effective treatment or combinations of treatments typically varies from patient to patient. For example, not all cancer patients respond to certain treatments like chemotherapy and radiation treatment, and furthermore not all responsive cancer patients have equal success with these treatments. The success of a treatment for a patient is often not known until the end of the treatment or after a follow-up period after the treatment. However, it is advantageous to be able to accurately predict whether a patient will respond well to a treatment, particularly earlier in the treatment plan, to guide implementation of alternative regimens and/or to abort an unsuccessful treatment plan. Accurate and frequent evaluation of a tumor's response to treatment allows a physician to optimize the treatment plan for the patient, and potentially spare an unresponsive patient from unnecessary side effects from the treatment, such as the physical and emotional toll of chemotherapy-induced side effects. Monitoring the state of tumor tissue in a patient could theoretically be performed with repeated use of magnetic resonance imaging (MRI) or positron emission tomography (PET). However, these technologies are costly and may not be accessible in a community for repeated use, making them ill-suited for frequent evaluation of tumor tissue. Other technologies, such as X-rays, utilize ionizing radiation that precludes frequent use. Thus, there is a need in the medical field to create an improved method of characterizing the pathological response of tissue to a treatment plan. This invention provides such an improved method.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a schematic of the method of a preferred embodiment;
  • FIG. 2 is a schematic of a scanner that may be used during the step of obtaining a set of sequential morphological renderings of tissue in the method of a preferred embodiment;
  • FIG. 3A, FIG. 3B, FIG. 3C, and FIG. 3D are schematics of steps of obtaining a set of sequential morphological renderings of tissue in the method of a preferred embodiment;
  • FIG. 4 is a schematic of the step of generating a set of representative values in the method of a preferred embodiment;
  • FIG. 5 and FIG. 6 are schematics of variations of determining a trend of the biomechanical property based on a set of representative values of a biomechanical property in the method of a preferred embodiment; and
  • FIG. 7 is a schematic of one variation of predicting response of tissue to a treatment plan based on the trend of a biomechanical property in the method of a preferred embodiment.
  • DETAILED DESCRIPTION
  • The following description of preferred embodiments of the invention is not intended to limit the invention to these preferred embodiments, but rather to enable any person skilled in the art to make and use this invention.
  • As shown in FIG. 1, the method 100 of characterizing the pathological response of tissue to a treatment plan of a preferred embodiment includes the steps of: obtaining a set of sequential morphology renderings of the tissue S110, wherein each rendering corresponds to a particular point in time during the treatment plan; generating a set of representative values of a biomechanical property of the tissue for the set of renderings S120, wherein each representative value is based on a corresponding rendering; determining a trend of the biomechanical property S130 based on the set of representative values; and predicting response of the tissue to the treatment plan S140 based on the trend of the biomechanical property. The method 100 is preferably used to predict and/or monitor the pathological response of cancer, such as breast cancer, to chemotherapy or radiation therapy (or side effects of the therapy), but may additionally and/or alternatively be used to predict or monitor the response of any cancer or benign tumors to any suitable treatment. The method 100 may additionally and/or alternatively be used to predict success of chemoprevention (a pharmacological approach to reducing cancer risk). Predicting and characterizing how a cancer patient will respond to a particular cancer treatment allows a physician to distinguish patients who are likely to have success with the treatment from those patients who are less likely to have success with the treatment, thereby allowing the physician to guide implementation of alternative regimens and/or to abort the particular treatment. Such knowledge about patient response to the treatment enables the physician to, for example, spare an unresponsive patient from suffering side effects of chemotherapy or radiation therapy and from applying potentially limited financial means towards an ineffective treatment, and move towards optimizing the efficacy of a treatment plan. The trend, such as rate of change, of the biomechanical property of the tumor early in the treatment plan is preferably used to predict the full treatment response, but the trend of the biomechanical property at any stage in the treatment plan may additionally and/or alternatively be used. The method 100 may facilitate an accurate and frequent evaluation of the tumor response to other therapies, such as to evaluate the clinical efficacy of a new therapeutic agent or regimen.
  • The step of obtaining a set of sequential morphology renderings S110 functions to obtain data from the patient. This data forms the basis of analysis in characterizing the response of the tissue to a cancer treatment. The morphology renderings preferably include renderings of tumor tissue, and may additionally and/or alternatively include renderings of healthy tissue such as that surrounding the tumor tissue. The morphology renderings may additionally and/or alternatively broken bones or any suitable tissue. Each rendering preferably corresponds to a particular point in time during the treatment plan, such that the set of renderings represent sequential, chronological snapshots of the tissue at various points in time during the treatment plan. For example, obtaining a rendering may be performed hourly, daily, every few days, every 1-3 weeks, or any suitable frequency, or performed in correspondence (e.g., immediately before and/or immediately after) a treatment phase such as a chemotherapy treatment. Obtaining a set of renderings S110 is preferably performed in early stages of a treatment plan (e.g., within the first several months), but may alternatively be performed during any suitable portion of the treatment plan. The set of renderings may be taken at approximately regular time intervals during the treatment plan, or at irregular time intervals (for example, the timing of the renderings may depend on particular scheduling of chemotherapy treatments). In a preferred embodiment, obtaining a set of renderings S110 preferably includes scanning the tissue with an ultrasound scanner to obtain acoustic data S112 and creating images representing acoustic parameters of the tissue with the acoustic data S114. The steps of scanning the tissue and creating images are each preferably performed at least once each time a single rendering is obtained, such that the steps of scanning the tissue and creating images are repeated multiple times. Obtaining a set of renderings S110 may additionally and/or alternatively include retrieving a set of images or renderings from a storage device such as a hard drive or an online server, or any suitable storage such as hard copy patient records.
  • The step of scanning the tissue S112 preferably includes surrounding the tissue with a transducer that transmits and receives acoustic waves through the tissue. For example, as shown in FIG. 2 and FIG. 3A, to scan breast tissue of a breast cancer patient with an ultrasound tomography scanner having a ring-shaped transducer, the patient positions themselves face down on a flexible bed having a hole in the chest region of the bed. The breast of the patient passes through the hole in the bed and is positioned within the transducer immersed in a water bath. The ring transducer is preferably fixed to a gantry, and, during the scanning step S112, moves in a vertical path to pass between the chest wall and the nipple region in an anterior-posterior direction, thereby preferably imaging the entire breast (alternatively a selected portion of the breast). The scanner is preferably similar to that described in U.S. Patent Publication No. 2008/0275344 entitled “Method and apparatus for categorizing breast density and assessing cancer risk utilizing acoustic parameters”, which is incorporated in its entirety by this reference. However, the ring transducer may be used to scan any suitable tissue, such as an arm, hand, leg, or foot. The scanner is preferably relatively inexpensive, quick, and more comfortable for the patient and easy to install and operate. The scanning step preferably gathers acoustic data including acoustic reflection from tissue, acoustic attenuation within tissue, and/or acoustic speed within tissue. However, the scanning step may additionally and/or alternatively gather any other acoustic data or suitable biomechanical property of the tissue. The method may alternatively include obtaining a set of morphology renderings using magnetic resonance imaging (MRI), positron emission tomography (PET), or any suitable device to generate renderings of tissue. For example, PET may be used to assess metabolic changes in tissue to generate tissue images.
  • The step of creating images representing acoustic parameters of the tissue S114 preferably includes generating one or more two-dimensional (2D) images from the acoustic data obtained during the scanning step, and may include generating one or more three-dimensional (3D) images of the tissue. In a preferred embodiment, as shown in FIG. 3C, generating one or more 2D images includes generating a plurality of 2D cross-sectional images (e.g., “slices” in the coronal plane, or any suitable plane) of the tissue S116 and combining the 2D cross-sectional images of the tissue into a 3D image of the tissue S118. The images are preferably tomography images, and more preferably ultrasound tomography images, although they may alternatively be any suitable tomography images. A general process for combining stacks of 2D images into a 3D image is known by one skilled in the art, but one possible process is described in U.S. Patent Publication No. 2008/0275344. Alternatively, the 2D and/or 3D images may be generated in any suitable manner. As shown in FIG. 3D, in the step of obtaining a set of sequential morphology renderings S110, the steps of scanning and creating images are preferably repeated until a chronological set of renderings of the tissue (preferably 3D) are obtained, such that the set includes a morphological rendering at times t1, t2, t3 . . . to are obtained. The images preferably represent at least one of acoustic reflection from the tissue, acoustic attenuation within the tissue, and acoustic speed within the tissue. However, the images may additionally and/or alternatively represent any suitable biomechanical property of the tissue. For example, the images may represent the tissue under Doppler radar or the interaction of the tissue with a contrast agent (e.g., uptake or kinetics of flow). As shown in FIG. 3B, each acoustic parameter is preferably imaged in a separate stack of 2D images, such that at each cross-sectional level in the stack, the images for acoustic reflection (Ir), attenuation (Ia), and/or acoustic speed (Is) can be overlaid or combined into a merged 2D image.
  • The step of generating a set of representative values of a biomechanical property S120 functions to quantify or otherwise characterize the biomechanical property in the set of renderings. As shown in FIG. 4, the step of generating a set of representative values S120 preferably includes calculating an average value of the biomechanical property for each rendering S122, thereby generating a set of sequential or chronological volume average values of the biomechanical property of the tissue. Generating a set of representative values S120 may further include normalizing the set of representative values, such as to remove statistical error from the measured data. The generated representative values of the set of renderings are preferably of acoustic speed, but may additionally and/or include acoustic attenuation, acoustic speed, tissue density, and/or any suitable biomechanical property. In a preferred embodiment, the average value is a volume average of the biomechanical property in a primary tumor in the patient. The primary tumor is preferably defined by locating an outline of the tumor mass as it appears on the morphology renderings of the acoustic reflection image, and the tumor outline may be replicated on the acoustic attenuation and/or acoustic speed morphology renderings to show the boundary of the primary tumor. The volume average preferably incorporates the mean value of the biomechanical property within the volume of the primary tumor as characterized by the renderings. For example, an average volumetric acoustic speed may be calculated as described in U.S. Patent Publication No. 2008/0275344. However, the volume average may be a representative value of the biomechanical property in the primary tumor calculated in any suitable manner. For example, the volume average may additionally and/or alternatively include other aspects, such as being weighted by a spatial distribution of the values of the biomechanical property throughout the primary tumor. In another example, the volume average may take into account a combination of multiple different kinds of biomechanical properties throughout the primary tumor.
  • In one variation, the average value may be the mean or other statistical average of multiple volume averages of the multiple tumors, or the maximum volume average value of the multiple volume averages of multiple tumors. In another variation, the average value is the mean or other statistical average of any suitable healthy or unhealthy portion of the rendered tissue. However, the average value may alternatively be any suitable average value.
  • Calculating an average value of the biomechanical property for each rendering S122 preferably includes accounting for the difference between the value of the biomechanical property within the tumor tissue and the value of the biomechanical property in background tissue surrounding the tumor tissue S124. Accounting for the difference functions to disregard the value of the biomechanical property in the background tissue. Preferably, accounting for the difference S124 includes subtracting an average value of the biomechanical property in background tissue from the volume average value of the biomechanical property of the tumor tissue S126, but the difference may be accounted for in any suitable manner. The boundary of background tissue relative to tumor tissue in each rendering may be defined in one or more of several manners. In one variation, the background tissue may be defined as a region beyond a distance threshold (e.g., 2 centimeters) beyond the boundary of the outlined tumor tissue. In another variation, the background tissue may be defined as a region beyond a boundary where the gradient in the biomechanical property satisfies a difference threshold. However, the boundary of background tissue relative to tumor tissue may be defined in any suitable manner.
  • In another variation, generating a set of representative values S120 includes determining an initial or baseline value of the biomechanical property, or any suitable singular value of the biomechanical property. For instance, the initial value may be taken from the first rendering obtained in step S110. Furthermore, determining a trend of the biomechanical property S130 may include characterizing initial values of multiple biomechanical properties, or any suitable singular values of multiple biomechanical properties.
  • Alternatively, generating a set of representative values S120 may include characterizing the spatial distribution of the biomechanical property in each of the set of renderings. The characterization may be qualitative, or may be quantitative such as by generating a parameter descriptive of the spatial distribution of the biomechanical property. Generating a set of representative values S120 may include characterizing the spatial distribution of acoustic speed in an acoustic rendering, but may additionally and/or alternatively include characterizing the spatial distribution of acoustic attenuation or any suitable biomechanical property.
  • The step of determining a trend of the biomechanical property S130 functions to generate metrics, based on the acoustic data, that may be analyzed for predicting or otherwise characterizing patient response to a treatment plan. Determining a trend S130 preferably includes calculating a rate of change in the set of average values S132, which may be one or more of several variations. In a first variation, as shown in FIG. 6, determining a trend of the biomechanical property S130 includes graphing the set of average values of the biomechanical property on a plot against a temporal variable (e.g., number of days of treatment or number of treatments) S134. Each value of the set of average values may be expressed as an absolute value, expressed as a percentage of the first average value of the set, or in any suitable manner. In this variation, calculating a rate of change S132 preferably includes calculating a slope of a best-fit curve fitted to at least a portion of the plot. In other words, the calculated rate of change in the biomechanical property may be the slope of a best-fit curve fitted to two or more values in the set of volume average values. Alternatively, the calculated rate of change may be the slope between the first and last average values, the mean or median of slopes between subsets of adjacent pairs of average values, percentage difference between two or more points on the plots, or any suitable statistical measure of rate of change in the plot. The calculated rate of change may or may not be displayed on the plot.
  • In a second variation, determining a trend of the biomechanical property S130 includes mathematically calculating the rate of change. The calculation may be similar to the first variation except the computation is performed without graphing the set of average values on a plot.
  • In a third variation, determining a trend of the biomechanical property S130 includes determining a trend of multiple biomechanical properties. For example, initial values of multiple biomechanical properties may be characterized relative to each other, such as by plotting (or comparing in any suitable manner, such as by calculating a ratio) the initial value of one biomechanical property against another biomechanical property. For example, in determining a trend of multiple biomechanical properties, the initial value of acoustic speed of the tissue may be compared to the initial value of acoustic attenuation of the tissue. Furthermore, as shown in FIG. 6, multiple time-dependent representative values (e.g., chronological average values) of one biomechanical property may be compared to those of another biomechanical property, such as on a multi-dimensional plot having time-dependent values of acoustic speed on one axis, time-dependent values of acoustic attenuation on another axis, and potentially a temporal variable on a third axis, or on a plot having a ratio of two biomechanical properties on one axis and a temporal variable on another axis.
  • In an alternative embodiment, determining a trend of the biomechanical property S132 may include graphing the set of average values of the biomechanical property on a plot against a temporal variable, similar to the plot of the first variation, and characterizing the general shape of the curve formed by the plot. The general shape (e.g., a plateau) of the curve may be characterized quantitatively and/or qualitatively. For example, the trend of the biomechanical property shown on the plot may be described as having a certain type of slope or plateau indicating an approximately degree of gradient or flatness, respectively.
  • The step of predicting response of the tissue S140 based on the trend of the biomechanical property functions to characterize the tissue response to the treatment plan. During the predicting step, the trend of the biomechanical property may be assessed for change in tissue properties, such as for long-term multiple stage intervention like chemotherapy and radiation therapy, or for cell death as a result of ablation interventions like cryotherapy, radiofrequency (RF) ablation, or electroporation. As shown in FIG. 7, predicting response of the tissue S140 preferably includes comparing the rate of change to a threshold S142. The threshold may be quantitative, or qualitative. The threshold is preferably based on data characterizing the response of prior patients to the treatment plan, such that prior patients undergoing the treatment plan form a baseline to which current patients may be compared. For example, thresholds may be determined with prior experimental data of patients who were scanned and analyzed according to the preferred method. Some or all of these prior patients may have completed the treatment plan, and additional means such as MRI or PET scans may have been used to determine whether these patients responded or did not respond to the treatment plan, and to what degree of success the responsive patients had with the treatment plan. Analysis of prior patients' experimental data may yield multiple thresholds that indicate varying thresholds of predicted responsiveness (e.g., “complete”, “partial”, or “nonresponsive”) to the treatment plan.
  • In a preferred variation, the threshold may be a “success” threshold, such that if the rate of change (or any singular value, such as an initial baseline value) of the biomechanical property is at and/or above the success threshold, the patient is predicted to respond positively to the continued treatment plan. Furthermore, in this variation, if the rate of change does not meet the success threshold, then the patient is predicted to not respond favorably to the treatment. The exact comparison of the rate of change or other trend relative to the threshold depends on the specific biomechanical property. For example, if the rate of change in acoustic speed in a primary tumor in a particular patient is a declining slope that is steeper than the slope of the success threshold, then the particular patient is predicted to respond positively to the continued treatment plan. However, for other biomechanical properties, the patient may be predicted to respond positively if the rate of change is an inclining slope that is steeper than the slope of the success threshold. Alternatively, the threshold may be considered a “fail” threshold.
  • Predicting response of the tissue S140 may be additionally and/or alternatively include any suitable characteristic of the set of average values of the biomechanical property. For example, in one alternative variation, predicting response of the tissue S140 includes analyzing the general shape of the curve formed by a plot of the set of average values against a temporal variable. In another variation, predicting response of the tissue S140 includes analyzing the initial starting value of biomechanical property in the set of average values. In yet another variation, predicting response of the tissue S140 includes analyzing the trend of one or more biomechanical property and/or morphological characteristic relative to another biomechanical property and/or morphological characteristic. For example, analyzing the trend may include analyzing the spread or distribution of values on a multi-dimensional plot that has values of one biomechanical property (e.g., acoustic speed) on one axis, values of another biomechanical property (e.g., acoustic attenuation), and potentially a temporal variable on a third axis. In another example, analyzing the trend may include analyzing the trend of the ratio between two biomechanical properties (or general shape of the curve formed by a plot of the ratios against a temporal variable).
  • The method may further include modifying the treatment plan based on the predicted response S150, which functions to utilize the predicted response of the tissue to most benefit the patient. For example, if the prediction is that the patient will respond favorably to the treatment plan, then the step of modifying the treatment plan based on the predicted response S150 may include maintaining the current treatment plan and/or continuing to monitor the physiological response of the patient. As another example, if the prediction is that the patient will not respond favorably to the treatment, then the step of modifying the treatment plan may include: altering characteristics of the treatment plan (such as type of dose, dosage amount, dosage frequency, or distribution pattern of radiation or ablation), administering a different kind of treatment, or aborting the treatment plan. Other suitable modifications, dependent on the specific nature and status of the patient as known by one skilled in the art, may be at the physician's discretion.
  • As a person skilled in the art will recognize from the previous detailed description and from the figures and claims, modifications and changes can be made to the preferred embodiments of the invention without departing from the scope of this invention defined in the following claims.

Claims (20)

What is claimed is:
1. A method of characterizing pathological response of a tumor in a volume of tissue to a treatment plan, comprising:
at a computing system in communication with an ultrasound system, generating a set of morphology renderings of the volume of tissue, from acoustic data received from the ultrasound system, wherein the set of morphology renderings is associated with a set of time points spanning at least a portion of the treatment plan;
at the computing system, generating a set of volume average values of a biomechanical property representative of a combination of acoustic speed with at least one of acoustic attenuation and acoustic reflection from the set of morphological renderings;
at the computing system, calculating a rate of change in the biomechanical property for the tumor from the set of volume average values; and
at the computing system, generating a predicted response of the tumor to the treatment plan based on the rate of change in the biomechanical property within the tumor.
2. The method of claim 1, wherein generating the set of morphology renderings includes suspending the volume of tissue within a bath having a ring transducer immersed in the bath, and passing the ring transducer along an anterior-posterior direction across the volume of tissue.
3. The method of claim 2, wherein generating the set of morphology renderings comprises 1) generating a plurality of two-dimensional cross-sectional images of the tumor and combining the cross-sectional images into a three-dimensional image of the tumor and 2) generating a merged image representing a combination of at least two of acoustic reflection, acoustic attenuation, and acoustic speed within the tumor.
4. The method of claim 1, wherein generating the set of volume average values includes generating at least one value based upon a combination of acoustic speed, acoustic attenuation, and acoustic reflection data for the tumor.
5. The method of claim 1, wherein calculating the rate of change in the biomechanical property within the tumor includes calculating a slope of a best-fit curve fitted to two or more values in the set of volume average values.
6. The method of claim 1, further comprising: at an output module of a user interface device in communication with the computing system, informing an entity of the predicted response, thereby enabling assessment of the treatment plan.
7. The method of claim 1, further comprising: by way of a display in communication with the computing system, automatically recommending an adjustment to the treatment plan, to an entity associated with a patient having the tumor, based upon a comparison between the rate of change in the biomechanical property and a success threshold slope.
8. The method of claim 7, wherein in automatically recommending the adjustment to the treatment plan, the success threshold slope is based upon a prior patient dataset characterizing response of prior patients to the treatment plan, wherein the prior patient dataset provides a set of thresholds indicative of predicted responsiveness to the treatment plan.
9. A method of characterizing the pathological response of a tissue to a treatment plan, comprising:
at a computing system in communication with an ultrasound system, obtaining a set of acoustic data, from the ultrasound system, associated with a set of time points spanning at least a portion of the treatment plan;
at the computing system, generating a set of renderings of the tissue based on the set of acoustic data, wherein each rendering in the set of morphology renderings corresponds to a time point of the set of time points;
at the computing system, for each rendering of the set of renderings, generating a quantitative value representative of a combination of acoustic speed with at least one of acoustic reflection and acoustic attenuation, thus generating a set of quantitative values spanning the set of time points;
at the computing system, calculating a trend across the set of quantitative values;
at the computing system, generating a predicted response of the tissue to the treatment plan based on the trend of the quantitative value, thereby characterizing the pathological response of the tissue to the treatment plan.
10. The method of claim 9, wherein determining the trend across the set of quantitative values includes analyzing a general shape of a curve formed by a plot of a set of average values, derived from the set of quantitative values, against a temporal variable.
11. The method of claim 9, wherein generating the predicted response of the tissue includes comparing the rate of change to a threshold, wherein comparing the rate of change to the threshold includes comparing the rate of change to the threshold that is based on data characterizing response of prior patients to the treatment plan.
12. The method of claim 9, wherein generating the set of quantitative values representative of the combination includes characterizing a spatial distribution of at least one biomechanical property in each rendering of the set of renderings.
13. The method of claim 9, wherein generating the set of quantitative values representative of the combination includes calculating a volume average value of at least one biomechanical property of the tissue for each rendering in the set of renderings, thereby generating a sequential set of volume average values.
14. The method of claim 9, wherein calculating the volume average value includes calculating the volume average value characterizing tumor tissue, thereby generating the sequential set of volume average values characterizing tumor tissue.
15. The method of claim 14, wherein calculating the volume average value characterizing tumor tissue includes accounting for a difference between a first value of a biomechanical property within the tumor tissue and a second value of the biomechanical property in background tissue surrounding the tumor tissue, wherein the boundary of background tissue is defined as a region separated from a boundary of the tumor tissue by a distance threshold that is less than 2 centimeters in length.
16. The method of claim 9, further comprising calculating a volume average value of breast density within the tissue for each rendering in the set of renderings, and generating the predicted response of the tissue to the treatment plan based on a second trend in breast density across the set of sequential morphology renderings.
17. The method of claim 9, wherein generating the set of renderings includes scanning the tissue with an ultrasound scanner of the ultrasound system and creating images representing acoustic parameters of the tissue with the acoustic data, wherein scanning the tissue includes surrounding breast tissue with a ring transducer and passing the ring transducer along an anterior-posterior direction relative to the breast tissue.
18. The method of claim 9, wherein generating the predicted response of the pathological mass to the treatment plan comprises determining a trend of a ratio between a first biomechanical property and a second biomechanical property, wherein the second biomechanical property is different from the first biomechanical property.
19. The method of claim 18, wherein determining the trend includes comparing a first trend of acoustic speed along a first axis of a multi-dimensional plot to a second trend of acoustic attenuation along a second axis of the multi-dimensional plot, wherein the multi-dimensional plot has a third axis corresponding to a temporal variable.
20. The method of claim 9, further comprising: by way of a display in communication with the computing system, automatically recommending an adjustment to the treatment plan, to an entity associated with a patient having the tissue, based upon a comparison between the rate of change in the quantitative value of the combination and a success threshold slope.
US16/367,362 2010-02-12 2019-03-28 Method of characterizing the pathological response of tissue to a treatment plan Abandoned US20200015775A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/367,362 US20200015775A1 (en) 2010-02-12 2019-03-28 Method of characterizing the pathological response of tissue to a treatment plan

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30425610P 2010-02-12 2010-02-12
US13/027,036 US9144403B2 (en) 2010-02-12 2011-02-14 Method of characterizing the pathological response of tissue to a treatment plan
US14/835,349 US10278672B2 (en) 2010-02-12 2015-08-25 Method of characterizing the pathological response of tissue to a treatment plan
US16/367,362 US20200015775A1 (en) 2010-02-12 2019-03-28 Method of characterizing the pathological response of tissue to a treatment plan

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/835,349 Continuation US10278672B2 (en) 2010-02-12 2015-08-25 Method of characterizing the pathological response of tissue to a treatment plan

Publications (1)

Publication Number Publication Date
US20200015775A1 true US20200015775A1 (en) 2020-01-16

Family

ID=44368190

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/027,036 Active US9144403B2 (en) 2010-02-12 2011-02-14 Method of characterizing the pathological response of tissue to a treatment plan
US14/835,349 Active 2032-12-28 US10278672B2 (en) 2010-02-12 2015-08-25 Method of characterizing the pathological response of tissue to a treatment plan
US16/367,362 Abandoned US20200015775A1 (en) 2010-02-12 2019-03-28 Method of characterizing the pathological response of tissue to a treatment plan

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US13/027,036 Active US9144403B2 (en) 2010-02-12 2011-02-14 Method of characterizing the pathological response of tissue to a treatment plan
US14/835,349 Active 2032-12-28 US10278672B2 (en) 2010-02-12 2015-08-25 Method of characterizing the pathological response of tissue to a treatment plan

Country Status (4)

Country Link
US (3) US9144403B2 (en)
JP (1) JP2013519454A (en)
CN (1) CN102843959B (en)
WO (1) WO2011100691A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011100691A1 (en) 2010-02-12 2011-08-18 Delphinus Medical Technologies, Inc. Method of characterizing the pathological response of tissue to a treatmant plan
CA2863675C (en) 2011-02-11 2019-04-23 E4 Endeavors, Inc. System and method for modeling a biopsy specimen
WO2013059358A2 (en) 2011-10-17 2013-04-25 Butterfly Network, Inc. Transmissive imaging and related apparatus and methods
EP2742855A1 (en) * 2012-12-11 2014-06-18 Friedrich-Alexander-Universität Erlangen-Nürnberg Brain functional magnetic resonance activity is associated with response to tumor necrosis factor inhibition
US9667889B2 (en) 2013-04-03 2017-05-30 Butterfly Network, Inc. Portable electronic devices with integrated imaging capabilities
US10143443B2 (en) * 2014-05-05 2018-12-04 Delphinus Medical Technologies, Inc. Method for representing tissue stiffness
EP3115766A1 (en) 2015-07-10 2017-01-11 3Scan Inc. Spatial multiplexing of histological stains
US11141132B2 (en) * 2016-06-23 2021-10-12 Hitachi, Ltd. Ultrasonic imaging device and ultrasonic imaging method using ultrasonic imaging device
US11298105B2 (en) 2017-09-07 2022-04-12 Delphinus Medical Technologies, Inc. System having anchored interface for shaping and positioning a tissue body
US20220212036A1 (en) * 2019-05-09 2022-07-07 The Regents Of The University Of Michigan Combined radiation acoustics and ultrasound for radiotherapy guidance and cancer targeting
CN115135230A (en) * 2019-12-17 2022-09-30 戴尔菲纳斯医疗科技公司 Method and system for cancer risk assessment using tissue sound velocity and stiffness
US11633630B2 (en) * 2020-01-23 2023-04-25 General Electric Company Noninvasive tissue displacement control and monitoring for neuromodulation

Family Cites Families (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3154067A (en) * 1961-10-11 1964-10-27 Robert L Gannon Body function sensor
US3771355A (en) 1971-09-30 1973-11-13 T Sachs Ultrasonic inspection and diagnosis system
US3881466A (en) * 1973-08-20 1975-05-06 Advanced Diagnostic Res Ultrasonic cross-sectional imaging system
US4059010A (en) * 1973-10-01 1977-11-22 Sachs Thomas D Ultrasonic inspection and diagnosis system
US3886489A (en) * 1974-02-25 1975-05-27 Westinghouse Electric Corp Ultrasonic image converter and system
US4028934A (en) * 1975-11-04 1977-06-14 Yeda Research & Development Co. Ltd. Ultrasonic stereoscopic imaging device
US4105018A (en) * 1976-02-02 1978-08-08 University Of Utah Acoustic examination, material characterization and imaging of the internal structure of a body by measurement of the time-of-flight of acoustic energy therethrough
US4075883A (en) * 1976-08-20 1978-02-28 General Electric Company Ultrasonic fan beam scanner for computerized time-of-flight tomography
FR2429436A1 (en) * 1978-06-20 1980-01-18 Anvar IMPROVEMENTS IN METHODS AND DEVICES FOR ULTRASONIC TRANSVERSE TOMOGRAPHY BY RECONSTRUCTION
US4222274A (en) * 1978-09-15 1980-09-16 Johnson Steven A Ultrasound imaging apparatus and method
US4317369A (en) * 1978-09-15 1982-03-02 University Of Utah Ultrasound imaging apparatus and method
US4515165A (en) * 1980-02-04 1985-05-07 Energy Conversion Devices, Inc. Apparatus and method for detecting tumors
EP0081527A4 (en) * 1981-06-22 1985-11-25 Commw Of Australia Improvements in or relating to ultrasound tomography.
US4433690A (en) * 1981-07-20 1984-02-28 Siemens Ag Compact ultrasound apparatus for medical examination
JPS58173539A (en) * 1982-04-07 1983-10-12 富士通株式会社 Measuring of characteristics of living body tissue by ultrasonic wave
US4431008A (en) 1982-06-24 1984-02-14 Wanner James F Ultrasonic measurement system using a perturbing field, multiple sense beams and receivers
DE3230897A1 (en) * 1982-08-19 1984-02-23 Siemens AG, 1000 Berlin und 8000 München ULTRASONIC TOMOGRAPHER
EP0111386B1 (en) * 1982-10-26 1987-11-19 University Of Aberdeen Ultrasound hyperthermia unit
US4562540A (en) * 1982-11-12 1985-12-31 Schlumberger Technology Corporation Diffraction tomography system and methods
US4542744A (en) * 1983-03-23 1985-09-24 North American Philips Corporation Method and apparatus for remote tissue identification by statistical modeling and hypothesis testing of echo ultrasound signals
US4671256A (en) * 1984-05-25 1987-06-09 Lemelson Jerome H Medical scanning, monitoring and treatment system and method
US4858124A (en) * 1984-08-15 1989-08-15 Riverside Research Institute Method for enhancement of ultrasonic image data
US4662222A (en) * 1984-12-21 1987-05-05 Johnson Steven A Apparatus and method for acoustic imaging using inverse scattering techniques
US5318024A (en) * 1985-03-22 1994-06-07 Massachusetts Institute Of Technology Laser endoscope for spectroscopic imaging
DE3525179A1 (en) 1985-07-15 1987-01-22 Siemens Ag METHOD AND DEVICE FOR ULTRASONIC SCANNING OF AN OBJECT
US4802487A (en) 1987-03-26 1989-02-07 Washington Research Foundation Endoscopically deliverable ultrasound imaging system
US4855911A (en) * 1987-11-16 1989-08-08 Massachusetts Institute Of Technology Ultrasonic tissue characterization
US4917096A (en) * 1987-11-25 1990-04-17 Laboratory Equipment, Corp. Portable ultrasonic probe
JPH0681616B2 (en) * 1988-05-26 1994-10-19 淑 中山 Ultrasonic diagnostic equipment
US5158071A (en) * 1988-07-01 1992-10-27 Hitachi, Ltd. Ultrasonic apparatus for therapeutical use
US4941474A (en) * 1988-07-01 1990-07-17 Massachusetts Institute Of Technology Multivariable analysis of bone condition
US5003979A (en) * 1989-02-21 1991-04-02 University Of Virginia System and method for the noninvasive identification and display of breast lesions and the like
US5143069A (en) * 1989-04-24 1992-09-01 Orthosonics, Inc. Diagnostic method of monitoring skeletal defect by in vivo acoustic measurement of mechanical strength using correlation and spectral analysis
US5562608A (en) 1989-08-28 1996-10-08 Biopulmonics, Inc. Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
US5029476A (en) * 1989-09-07 1991-07-09 Westinghouse Electric Corp. Ultrasonic system for determining the profile of solid bodies
US5107837A (en) * 1989-11-17 1992-04-28 Board Of Regents, University Of Texas Method and apparatus for measurement and imaging of tissue compressibility or compliance
US5103129A (en) 1990-07-26 1992-04-07 Acoustic Imaging Technologies Corporation Fixed origin biplane ultrasonic transducer
JP3231810B2 (en) * 1990-08-28 2001-11-26 アーチ・デベロップメント・コーポレーション Differential diagnosis support method using neural network
US5280788A (en) * 1991-02-26 1994-01-25 Massachusetts Institute Of Technology Devices and methods for optical diagnosis of tissue
US5305752A (en) * 1991-05-31 1994-04-26 Thermotrex Corporation Acoustic imaging device
US5268876A (en) * 1991-06-25 1993-12-07 The Board Of Trustees Of The Leland Stanford Junior University Method of estimating near field aberrating delays
US5260871A (en) * 1991-07-31 1993-11-09 Mayo Foundation For Medical Education And Research Method and apparatus for diagnosis of breast tumors
US5415164A (en) * 1991-11-04 1995-05-16 Biofield Corp. Apparatus and method for screening and diagnosing trauma or disease in body tissues
US5329817A (en) * 1991-11-22 1994-07-19 Advanced Imaging Systems Ultrasonic holography imaging method and apparatus
US5212571A (en) * 1991-11-22 1993-05-18 Advanced Imaging Systems Ultrasonic holographic imaging apparatus having zoom feature
US5179455A (en) * 1991-11-22 1993-01-12 Advanced Imaging Systems Ultrasonic holographic imaging apparatus having an improved optical reconstruction system
US5289520A (en) * 1991-11-27 1994-02-22 Lorad Corporation Stereotactic mammography imaging system with prone position examination table and CCD camera
US5269309A (en) * 1991-12-11 1993-12-14 Fort J Robert Synthetic aperture ultrasound imaging system
DE69227463T2 (en) * 1991-12-17 1999-06-10 Dynamics Imaging Inc METHOD AND DEVICE FOR DIAGNOSIS OF LIVING ORGANISMS
US5255683A (en) * 1991-12-30 1993-10-26 Sound Science Limited Partnership Methods of and systems for examining tissue perfusion using ultrasonic contrast agents
US6023632A (en) * 1997-07-16 2000-02-08 Wilk; Peter J. Ultrasonic medical system and associated method
WO1993016641A1 (en) * 1992-02-21 1993-09-02 Diasonics, Inc. Ultrasound intracavity system for imaging therapy planning and treatment of focal disease
JP3325300B2 (en) * 1992-02-28 2002-09-17 株式会社東芝 Ultrasound therapy equipment
DE4207463C2 (en) * 1992-03-10 1996-03-28 Siemens Ag Arrangement for the therapy of tissue with ultrasound
US5297553A (en) 1992-09-23 1994-03-29 Acuson Corporation Ultrasound transducer with improved rigid backing
US5339282A (en) * 1992-10-02 1994-08-16 University Of Utah Research Foundation Resolution enhancement for ultrasonic reflection mode imaging
US5296910A (en) 1992-10-05 1994-03-22 University Of Akransas Method and apparatus for particle analysis
US6587540B1 (en) 1992-10-14 2003-07-01 Techniscan, Inc. Apparatus and method for imaging objects with wavefields
US6005916A (en) * 1992-10-14 1999-12-21 Techniscan, Inc. Apparatus and method for imaging with wavefields using inverse scattering techniques
US5588032A (en) * 1992-10-14 1996-12-24 Johnson; Steven A. Apparatus and method for imaging with wavefields using inverse scattering techniques
US5620479A (en) * 1992-11-13 1997-04-15 The Regents Of The University Of California Method and apparatus for thermal therapy of tumors
US5678565A (en) * 1992-12-21 1997-10-21 Artann Corporation Ultrasonic elasticity imaging method and device
US6002958A (en) * 1992-12-24 1999-12-14 Dynamics Imaging, Inc. Method and apparatus for diagnostics of internal organs
US5365429A (en) 1993-01-11 1994-11-15 North American Philips Corporation Computer detection of microcalcifications in mammograms
US5573497A (en) * 1994-11-30 1996-11-12 Technomed Medical Systems And Institut National High-intensity ultrasound therapy method and apparatus with controlled cavitation effect and reduced side lobes
JP3860227B2 (en) * 1993-03-10 2006-12-20 株式会社東芝 Ultrasonic therapy device used under MRI guide
DE69431741T2 (en) * 1993-03-12 2003-09-11 Toshiba Kawasaki Kk Device for medical treatment with ultrasound
US5413108A (en) * 1993-04-21 1995-05-09 The Research Foundation Of City College Of New York Method and apparatus for mapping a tissue sample for and distinguishing different regions thereof based on luminescence measurements of cancer-indicative native fluorophor
US5433202A (en) * 1993-06-07 1995-07-18 Westinghouse Electric Corporation High resolution and high contrast ultrasound mammography system with heart monitor and boundary array scanner providing electronic scanning
US5318028A (en) * 1993-06-07 1994-06-07 Westinghouse Electric Corporation High resolution ultrasound mammography system and boundary array scanner therefor
US5596992A (en) * 1993-06-30 1997-01-28 Sandia Corporation Multivariate classification of infrared spectra of cell and tissue samples
US5349954A (en) * 1993-07-23 1994-09-27 General Electric Company Tumor tissue characterization apparatus and method
US5474072A (en) * 1993-10-29 1995-12-12 Neovision Corporation Methods and apparatus for performing sonomammography
CA2173154C (en) * 1993-10-29 2010-03-23 Ascher Shmulewitz Methods and apparatus for performing sonomammography and enhanced x-ray imaging
ZA948393B (en) * 1993-11-01 1995-06-26 Polartechnics Ltd Method and apparatus for tissue type recognition
JPH07184907A (en) 1993-12-28 1995-07-25 Toshiba Corp Ultrasonic treating device
US5865743A (en) * 1994-02-23 1999-02-02 Dynamics Imaging, Inc. Method of living organism multimodal functional mapping
JP3378082B2 (en) 1994-04-12 2003-02-17 富士通株式会社 Ultrasound diagnostic probe
US5673698A (en) 1994-04-21 1997-10-07 Hitachi Medical Corporation Multichannel ultrasonic diagnosis apparatus
US5487387A (en) * 1994-06-03 1996-01-30 Duke University Method and apparatus for distinguishing between solid masses and fluid-filled cysts
DE19530116C2 (en) * 1994-09-14 2000-04-27 Siemens Ag Device for displaying sound propagation times
US6176842B1 (en) 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
US5797849A (en) * 1995-03-28 1998-08-25 Sonometrics Corporation Method for carrying out a medical procedure using a three-dimensional tracking and imaging system
US5833627A (en) 1995-04-13 1998-11-10 United States Surgical Corporation Image-guided biopsy apparatus and methods of use
US5660185A (en) 1995-04-13 1997-08-26 Neovision Corporation Image-guided biopsy apparatus with enhanced imaging and methods
US5558092A (en) * 1995-06-06 1996-09-24 Imarx Pharmaceutical Corp. Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously
US5640956A (en) * 1995-06-07 1997-06-24 Neovision Corporation Methods and apparatus for correlating ultrasonic image data and radiographic image data
US7841982B2 (en) 1995-06-22 2010-11-30 Techniscan, Inc. Apparatus and method for imaging objects with wavefields
US5582173A (en) * 1995-09-18 1996-12-10 Siemens Medical Systems, Inc. System and method for 3-D medical imaging using 2-D scan data
US5606971A (en) * 1995-11-13 1997-03-04 Artann Corporation, A Nj Corp. Method and device for shear wave elasticity imaging
US5810731A (en) * 1995-11-13 1998-09-22 Artann Laboratories Method and apparatus for elasticity imaging using remotely induced shear wave
US5895356A (en) 1995-11-15 1999-04-20 American Medical Systems, Inc. Apparatus and method for transurethral focussed ultrasound therapy
EP0883860B1 (en) 1996-02-29 2006-08-23 Acuson Corporation Multiple ultrasound image registration system, method and transducer
JP3537594B2 (en) * 1996-06-13 2004-06-14 アロカ株式会社 Ultrasonic diagnostic equipment
US5749364A (en) * 1996-06-21 1998-05-12 Acuson Corporation Method and apparatus for mapping pressure and tissue properties
US5846202A (en) * 1996-07-30 1998-12-08 Acuson Corporation Ultrasound method and system for imaging
WO1998012667A2 (en) 1996-08-29 1998-03-26 Johnson Steven A Wavefield imaging using inverse scattering techniques
RU2132635C1 (en) * 1996-09-30 1999-07-10 Алексеев Сергей Григорьевич Method and device for diagnosing oncological diseases
US5713356A (en) * 1996-10-04 1998-02-03 Optosonics, Inc. Photoacoustic breast scanner
US5776062A (en) 1996-10-15 1998-07-07 Fischer Imaging Corporation Enhanced breast imaging/biopsy system employing targeted ultrasound
US6056690A (en) * 1996-12-27 2000-05-02 Roberts; Linda M. Method of diagnosing breast cancer
US5891619A (en) * 1997-01-14 1999-04-06 Inphocyte, Inc. System and method for mapping the distribution of normal and abnormal cells in sections of tissue
US6109270A (en) * 1997-02-04 2000-08-29 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Multimodality instrument for tissue characterization
US5855554A (en) * 1997-03-17 1999-01-05 General Electric Company Image guided breast lesion localization device
US6117080A (en) * 1997-06-04 2000-09-12 Atl Ultrasound Ultrasonic imaging apparatus and method for breast cancer diagnosis with the use of volume rendering
US5833614A (en) * 1997-07-15 1998-11-10 Acuson Corporation Ultrasonic imaging method and apparatus for generating pulse width modulated waveforms with reduced harmonic response
US6317617B1 (en) 1997-07-25 2001-11-13 Arch Development Corporation Method, computer program product, and system for the automated analysis of lesions in magnetic resonance, mammogram and ultrasound images
US6256090B1 (en) 1997-07-31 2001-07-03 University Of Maryland Method and apparatus for determining the shape of a flexible body
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6050943A (en) * 1997-10-14 2000-04-18 Guided Therapy Systems, Inc. Imaging, therapy, and temperature monitoring ultrasonic system
US6083166A (en) * 1997-12-02 2000-07-04 Situs Corporation Method and apparatus for determining a measure of tissue manipulation
US6289235B1 (en) 1998-03-05 2001-09-11 Wake Forest University Method and system for creating three-dimensional images using tomosynthetic computed tomography
EP1063920B1 (en) 1998-03-20 2006-11-29 Barbara Ann Karmanos Cancer Institute Multidimensional detection and characterization of pathologic tissues
US6385474B1 (en) 1999-03-19 2002-05-07 Barbara Ann Karmanos Cancer Institute Method and apparatus for high-resolution detection and characterization of medical pathologies
US6135960A (en) * 1998-08-31 2000-10-24 Holmberg; Linda Jean High-resolution, three-dimensional whole body ultrasound imaging system
US6245017B1 (en) 1998-10-30 2001-06-12 Kabushiki Kaisha Toshiba 3D ultrasonic diagnostic apparatus
US6149441A (en) * 1998-11-06 2000-11-21 Technology For Connecticut, Inc. Computer-based educational system
US6574499B1 (en) 1998-11-25 2003-06-03 Xdata Corporation Mammography method and apparatus
US6413219B1 (en) 1999-03-31 2002-07-02 General Electric Company Three-dimensional ultrasound data display using multiple cut planes
US6296489B1 (en) 1999-06-23 2001-10-02 Heuristix System for sound file recording, analysis, and archiving via the internet for language training and other applications
EP1207788A4 (en) 1999-07-19 2009-12-09 St Jude Medical Atrial Fibrill Apparatus and method for ablating tissue
US6368275B1 (en) 1999-10-07 2002-04-09 Acuson Corporation Method and apparatus for diagnostic medical information gathering, hyperthermia treatment, or directed gene therapy
DE19963440C2 (en) 1999-12-28 2003-02-20 Siemens Ag Method and system for visualizing an object
US6511427B1 (en) 2000-03-10 2003-01-28 Acuson Corporation System and method for assessing body-tissue properties using a medical ultrasound transducer probe with a body-tissue parameter measurement mechanism
AU2001245831A1 (en) 2000-03-15 2001-09-24 The Regents Of The University Of California Method and apparatus for dynamic focusing of ultrasound energy
US6351660B1 (en) 2000-04-18 2002-02-26 Litton Systems, Inc. Enhanced visualization of in-vivo breast biopsy location for medical documentation
US6450960B1 (en) 2000-08-29 2002-09-17 Barbara Ann Karmanos Cancer Institute Real-time three-dimensional acoustoelectronic imaging and characterization of objects
US6964647B1 (en) 2000-10-06 2005-11-15 Ellaz Babaev Nozzle for ultrasound wound treatment
US8211020B2 (en) 2000-10-11 2012-07-03 University of Pittsburgh—of the Commonwealth System of Higher Education Combining tomographic images in situ with direct vision in sterile environments
DE10050232A1 (en) 2000-10-11 2002-05-02 Karlsruhe Forschzent High-resolution ultrasound tomograph
US7556602B2 (en) 2000-11-24 2009-07-07 U-Systems, Inc. Breast cancer screening with adjunctive ultrasound mammography
US6475150B2 (en) 2000-12-01 2002-11-05 The Regents Of The University Of California System and method for ultrasonic tomography
US6785570B2 (en) 2000-12-22 2004-08-31 Md Medical Diagnostics Inc. System and method for analysis of a tissue
US7179449B2 (en) 2001-01-30 2007-02-20 Barnes-Jewish Hospital Enhanced ultrasound detection with temperature-dependent contrast agents
US6939301B2 (en) 2001-03-16 2005-09-06 Yaakov Abdelhak Automatic volume measurements: an application for 3D ultrasound
US6478739B1 (en) 2001-05-11 2002-11-12 The Procter & Gamble Company Ultrasonic breast examination system
US7460605B2 (en) 2001-11-15 2008-12-02 Lawrence Livermore National Security, Llc Time reversal communication system
US6559178B1 (en) 2002-01-29 2003-05-06 Mark Zamoyski Compositions and methods for apoptotic chemosurgery
US6776760B2 (en) 2002-03-06 2004-08-17 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Multi-mode processing for ultrasonic imaging
US6878115B2 (en) 2002-03-28 2005-04-12 Ultrasound Detection Systems, Llc Three-dimensional ultrasound computed tomography imaging system
WO2003096883A2 (en) 2002-05-16 2003-11-27 Barbara Ann Karmanos Cancer Institute Combined diagnostic and therapeutic ultrasound system
US7285092B2 (en) 2002-12-18 2007-10-23 Barbara Ann Karmanos Cancer Institute Computerized ultrasound risk evaluation system
US20040059265A1 (en) 2002-09-12 2004-03-25 The Regents Of The University Of California Dynamic acoustic focusing utilizing time reversal
US6883194B2 (en) 2002-11-08 2005-04-26 Art Advanced Research And Technology Inc. Method and apparatus for positioning a patient on a table for a medical procedure on a breast
US6837854B2 (en) 2002-12-18 2005-01-04 Barbara Ann Karmanos Cancer Institute Methods and systems for using reference images in acoustic image processing
US20040122708A1 (en) * 2002-12-18 2004-06-24 Avinash Gopal B. Medical data analysis method and apparatus incorporating in vitro test data
US20040122704A1 (en) * 2002-12-18 2004-06-24 Sabol John M. Integrated medical knowledge base interface system and method
US6926672B2 (en) 2002-12-18 2005-08-09 Barbara Ann Karmanos Cancer Institute Electret acoustic transducer array for computerized ultrasound risk evaluation system
EP1594404B1 (en) 2003-01-23 2013-09-11 3G Ultrasound, Inc. Ultrasonic imaging device and system
DE10305603B4 (en) 2003-02-11 2009-12-03 Siemens Ag Device for generating a three-dimensional ultrasound image
US20040167396A1 (en) 2003-02-25 2004-08-26 The Regents Of The University Of California Quantitative full aperture tomography imaging system and method
US20040181154A1 (en) 2003-03-13 2004-09-16 Roy Peterson Ultrasonic diagnostic imaging devices with fuel cell energy source
US7601122B2 (en) 2003-04-22 2009-10-13 Wisconsin Alumni Research Foundation Ultrasonic elastography with angular compounding
US8021303B2 (en) 2003-06-12 2011-09-20 Bracco Research Sa System for extracting morphological information through a perfusion assessment process
WO2004112577A2 (en) 2003-06-20 2004-12-29 U-Systems, Inc. Full-field breast ultrasound system and architecture
JP4434668B2 (en) * 2003-09-10 2010-03-17 株式会社東芝 Treatment system and treatment support system
US7346203B2 (en) 2003-11-19 2008-03-18 General Electric Company Methods and apparatus for processing image data to aid in detecting disease
US7497830B2 (en) 2003-11-21 2009-03-03 Koninklijke Philips Electronics N.V. Three dimensional ultrasonic imaging using mechanical probes with beam scanning reversal
WO2005057467A2 (en) * 2003-12-02 2005-06-23 Subqiview Inc. Tissue characterization using an eddy-current probe
JP4602993B2 (en) 2004-01-16 2010-12-22 ボストン サイエンティフィック リミテッド Method and apparatus for medical imaging
US7492932B2 (en) 2004-03-05 2009-02-17 Nortel Networks Ltd. Method and apparatus for processing medical image data in a network environment
JP2005253827A (en) 2004-03-15 2005-09-22 Fuji Photo Film Co Ltd Ultrasonic imaging method and equipment
US20060009693A1 (en) 2004-04-08 2006-01-12 Techniscan, Inc. Apparatus for imaging and treating a breast
DK1773978T3 (en) 2004-05-19 2014-05-26 Univ Pittsburgh Perfused, three-dimensional cell / tissue disease models
JP4786150B2 (en) 2004-07-07 2011-10-05 株式会社東芝 Ultrasonic diagnostic apparatus and image processing apparatus
US7662097B2 (en) * 2004-09-20 2010-02-16 Resonant Medical, Inc. Radiotherapy treatment monitoring using ultrasound
US7865236B2 (en) * 2004-10-20 2011-01-04 Nervonix, Inc. Active electrode, bio-impedance based, tissue discrimination system and methods of use
CA2588182C (en) * 2004-12-23 2014-05-06 Bracco Research Sa A perfusion assessment method and system based on bolus administration
WO2007002696A2 (en) 2005-06-28 2007-01-04 Kaiser Daniel E Decompressive thermogenic bandage
EP1921982A2 (en) 2005-08-25 2008-05-21 Koninklijke Philips Electronics N.V. 4d image-based planning methods and apparatus for targeted therapy
US20070167823A1 (en) 2005-12-20 2007-07-19 General Electric Company Imaging catheter and method for volumetric ultrasound
US7620227B2 (en) 2005-12-29 2009-11-17 General Electric Co. Computer-aided detection system utilizing temporal analysis as a precursor to spatial analysis
US20080229832A1 (en) 2007-02-16 2008-09-25 Los Alamos National Security Automatic time-of-flight selection for ultrasound tomography
CA2683805C (en) * 2007-04-13 2014-09-23 The Regents Of The University Of Michigan Systems and methods for tissue imaging
US7769464B2 (en) * 2007-04-30 2010-08-03 Medtronic, Inc. Therapy adjustment
US8870771B2 (en) * 2007-05-04 2014-10-28 Barbara Ann Karmanos Cancer Institute Method and apparatus for categorizing breast density and assessing cancer risk utilizing acoustic parameters
US8366617B2 (en) 2007-05-15 2013-02-05 CVUS Clinical Trials, LLC Breast scanning system
US7912264B2 (en) 2007-08-03 2011-03-22 Siemens Medical Solutions Usa, Inc. Multi-volume rendering of single mode data in medical diagnostic imaging
US8565856B2 (en) 2007-09-18 2013-10-22 Siemens Medical Solutions Usa, Inc. Ultrasonic imager for motion measurement in multi-modality emission imaging
EP2211721B1 (en) 2007-11-19 2019-07-10 Pyronia Medical Technologies, Inc. Patient positioning system and methods for diagnostic radiology and radiotherapy
JP4465018B2 (en) 2008-09-09 2010-05-19 オリンパスメディカルシステムズ株式会社 Ultrasonic diagnostic equipment
JP2009076102A (en) * 2008-12-22 2009-04-09 Toshiba Corp Medical information providing system
WO2011100691A1 (en) 2010-02-12 2011-08-18 Delphinus Medical Technologies, Inc. Method of characterizing the pathological response of tissue to a treatmant plan
US20130267850A1 (en) 2010-12-06 2013-10-10 Michael Berman System and method for ultrasonic examination of the breast
EP2964086A4 (en) 2013-03-09 2017-02-15 Kona Medical, Inc. Transducers, systems, and manufacturing techniques for focused ultrasound therapies

Also Published As

Publication number Publication date
US10278672B2 (en) 2019-05-07
US20150359508A1 (en) 2015-12-17
CN102843959B (en) 2014-11-12
CN102843959A (en) 2012-12-26
WO2011100691A1 (en) 2011-08-18
JP2013519454A (en) 2013-05-30
US9144403B2 (en) 2015-09-29
US20110201928A1 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
US20200015775A1 (en) Method of characterizing the pathological response of tissue to a treatment plan
US20230089236A1 (en) Method of characterizing tissue of a patient
EP3806721B1 (en) Method and system for determining fractional fat content of tissue
RU2633322C2 (en) System and method of hybrid surface radiotherapy with ultrasound control
Duric et al. Breast density measurements with ultrasound tomography: A comparison with film and digital mammography
KR101900122B1 (en) Ultrasound apparatus for assessing the quality of a patient’s bone tissue
US20150313577A1 (en) Method for representing tissue stiffness
EP2533683A1 (en) Method of characterizing the pathological response of tissue to a treatmant plan
WO2021048776A1 (en) Method for evaluating the presence of sarcopenia by magnetic resonance or echography or computed tomography
Xiao et al. Simple ways to estimate meningioma volume: can abc-and sh-derived methods be used in clinical practice reliably?
Rodriguez et al. Skeletal muscle estimation: A review of techniques and their applications
AU2019331078B2 (en) System and method for identifying fluid retention in a body part
US20220327706A1 (en) Method and Apparatus for Optimizing the Use of Contrast Agents during Medical Imaging
RU2449724C1 (en) Method of estimating efficiency of diffuse mastopatia treatment
WO2023081917A1 (en) Methods and systems of generating perfusion parametric maps
WO2012092581A1 (en) Normalized metrics for visceral adipose tissue mass and volume estimation

Legal Events

Date Code Title Description
AS Assignment

Owner name: DELPHINUS MEDICAL TECHNOLOGIES, INC., MICHIGAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DURIC, NEBOJSA;LITTRUP, PETER JOHN;REEL/FRAME:049773/0692

Effective date: 20150908

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION